PNS4 The Consequences of Greater Net Price Transparency for Innovative Medicines: Insights from European Experts and Payers

Abstract

Authors

M. Pistollato K. Ross-Stewart H. Ahir

Full Text Cite This Article
Back to Volume 24, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×